Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day

Rongju Liu1*, Liling Zhou1, Xuemei Chen1, Hongmei He1,2 and Zhaowei Cai1

1 Reproductive Medical Center, Dongguan Songshan Lake (SSL) Central Hospital, Dongguan City, China, 2 The Second School of Clinical Medicine, Southern Medical University, Guangzhou City, China

Although using letrozole (LE) during in vitro fertilisation and intracytoplasmic sperm injection (IVF/ICSI) has many advantages, it remains unclear whether LE induces an increase in progestogen during the late follicular phase. The objective of this study was to investigate whether progesterone levels increased under antagonist protocols supplemented with LE on the trigger day using a retrospective cohort study. The study included 1,133 women who underwent IVF/ICSI cycles from January 2018 to June 2020. After propensity score matching (PSM) for baseline characteristics, 266 patients with gonadotropin-releasing hormone-antagonist (GnRH-ant) were matched to 266 patients with letrozole + GnRH-ant (LE GnRH-ant) (PSM 1 cohort), and 283 patients with GnRH-agonist (GnRH-a) were matched to 283 patients with LE GnRH-ant (PSM 2 cohort). In the PSM 1 cohort, patients in the LE GnRH-a group presented higher progesterone levels (1.22 ± 0.95 ng/mL vs 0.86 ± 0.60 ng/mL, P < 0.001), with a higher proportion of patients with progesterone level > 1.5 ng/mL (24.81% vs 7.52%, P < 0.001). In PSM 2 cohort, patients in the LE GnRH-a group presented higher progesterone levels on trigger day (1.23 ± 0.91 ng/mL vs 0.98 ± 0.61 ng/mL, P < 0.001), with a higher proportion of patients with progesterone level > 1.5 ng/mL (25.45% vs 12.70%, P < 0.001). In the PSM 1 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL, with an increase in every retrieved oocyte in the LE GnRH-ant group (b 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-ant group (b 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001), with P for interaction being 0.0018. In the PSM 2 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL with an increase in every retrieved oocyte in the LE GnRH-ant group (b 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-a group (b 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001), with P for interaction being 0.0002. LE supplementation on the antagonist protocols may increase progesterone levels in the late follicular stage.

Keywords: IVF/ICSI, ovarian stimulation, letrozole, progesterone, trigger day
INTRODUCTION

Letrozole (LE) is a drug commonly used to induce ovulation. It is a selective aromatase inhibitor that blocks oestrogen biosynthesis and indirectly increases pituitary secretion of follicle-stimulating hormone (FSH), thus increasing FSH stimulation to the ovary and promoting follicular development (1). Letrozole also enhances intrafollicular androgen levels, which up-regulate and sensitise FSH receptors in the ovary and stimulate activin secretion (2). A meta-analysis confirmed the efficacy and safety of controlled ovarian stimulation (COS) with gonadotropins and LE, considering the number of oocytes retrieved from mature metaphase II, total number of retrieved oocytes, the maturation rate, the fertilisation rate, and the lack of evidence of its harm to the foetus (3, 4).

Using LE during in vitro fertilisation and intracytoplasmic sperm injection (IVF/ICSI) treatment has many advantages. First, LE is used to prepare the endometrium in the frozen embryo transfer (FET) cycle, and no negative effect on endometrial receptivity has yet been reported (5–8). Some studies revealed that clinical pregnancy rates and live birth rates in the LE group are significantly higher, and the rate of miscarriage is significantly lower compared to those in the natural and hormone replacement cycle groups (9, 10). Second, LE significantly lowers the level of oestradiol and prevents ovarian hyperstimulation syndrome (11), exerting protective effects in patients with breast cancer (12). Third, adding LE to normal responders can reduce the dosage of gonadotropins, without affecting gravidity (13).

Letrozole competitively binds to the heme group of the cytochrome P450 subunit of aromatase, blocking the conversion of androstenedione and testosterone to oestrone and oestradiol, leading to an increase in androgen and a decrease in oestrogen levels (14). Therefore, LE is commonly used to promote ovulation under conditions of low ovarian reserve to increase the ovarian response to FSH (1, 12). Although high levels of progesterone have been related to using LE during the luteal phase (15, 16), it remains unclear whether LE induces an increase in progesterone during the late follicular phase. In some randomised controlled trials (RCT), LE use in normal responders did not significantly up-regulate progesterone on trigger day (17, 18). Other RCTs showed that LE supplementation increases the incidence of premature progesterone rise in the late follicular phase of IVF/ICSI (19) or increases progesterone levels (14, 20). Reports on the effects of LE on progesterone levels during ovulation induction are inconsistent, largely because the above findings are based on RCTs with small sample sizes. In addition, the progesterone level during ovulation induction was not the main outcome measure in those studies, and the power of test is insufficient. Finally, the different eligibility criteria of the studies limit extrapolations of the results.

The purpose of this study was to determine whether the LE antagonist protocol would increase progesterone levels on the trigger day of ovulation induction in various patients. This study may be useful in improving LE use.

MATERIALS AND METHODS

Study Design and Patients

This retrospective cohort study was conducted at the Reproductive Medical Centre, Dongguan SSL Central Hospital, Guangdong, China, and included 1,362 IVF/ICSI cycles between January 2018 and June 2020. All patients were in the first cycle. Among them, 1,186 cycles followed a gonadotropin-releasing hormone-agonist (GnRH-a) or gonadotropin-releasing hormone-antagonist (GnRH-ant) protocol. Females with congenital adrenal hyperplasia, luteinising hormone (LH) levels > 2.5 times the baseline levels on trigger day, a malformed uterus, or an abnormal chromosome were excluded. Based on different ovulation induction protocols, 1,133 infertile women who underwent ovarian stimulation were divided into the following groups: GnRH-a (383), GnRH-ant (390), and LE GnRH-ant (360) (Figure 1).

Data Collection

Age, duration of infertility, body mass index (BMI), anti-Mullerian hormone (AMH) levels during menstruation, factors of infertility, and treatment intervention features (including total gonadotropins, stimulation days, total retrieved oocytes, and hormone levels on trigger day) were collected from the hospital’s medical record system. Patients were followed up routinely until either the occurrence of menstrual periods or childbirth. Follow-ups were censored on 15 April 2021.
Patients on the GnRH-a protocol were administered 0.8–1.5 mg of triptorelin during the mid-luteal phase of the preceding in vitro fertilisation-embryo transfer (IVF-ET) cycle. Fourteen days later, the initial dose of 125–300 IU recombinant FSH (rFSH, Gonal F, Merck Serono, Switzerland) was determined based on patient characteristics (age, BMI, AMH, and the antral follicle count).

Patients in the GnRH-ant protocol received daily intramuscular injections of rFSH (125–300 IU) from the first day of stimulation to the day of human chorionic gonadotropin (hCG) administration. When the lead follicle was 14 mm or more in diameter or oestradiol levels were ≥ 400 pg/mL, patients received 0.25 mg of antagonist (Cetrotide; Merk Serono, Switzerland) until they were triggered by hCG (Chorionic Gonadotrophin, Lizhu, China).

Some patients on the GnRH-ant protocol were co-treated with 2.5 mg of LE (Jiangsu, Hengrui, China), which they received daily for four days from stimulation day 1, to reduce costs and increasing ovarian sensitivity.

The administration of FSH was ceased following the appearance of three leading follicles (at least 17 mm in diameter) and 6000–10,000 IU of hCG was subsequently administered. The ovarian response to this therapy was monitored by measuring LH, FSH, serum oestradiol, and progesterone levels and transvaginal ultrasonography. Oocytes were retrieved 35 to 36 h after hCG injection.

**Hormone Level Detection**

All hormone levels were measured using a detection kit using electrochemiluminescence (Cobas e411, Roche, Germany). The detection steps were performed under the manufacturer’s instructions. Mean percent intra-assay and inter-assay coefficient of variations, respectively, were 1.8% and 5.2% for LH, 1.8% and 5.3% for FSH, 3.1% and 3.4% for oestradiol, 3.3% and 10.4% for progesterone, 2.1% and 3.2% for testosterone. The low detection limits were 0.100 mIU/mL for LH, 0.100 mIU/mL for FSH, 5 pg/mL for oestradiol, 0.05 ng/mL for progesterone, 0.025 ng/mL for testosterone.

**Statistical Analysis**

Propensity score matching (PSM) was performed to balance the factors related to progesterone levels on trigger day. To reduce sample loss, we conducted a pairwise comparison. Propensity score matching was conducted to balance LE GnRH-ant and GnRH-ant groups to form the PSM 1 cohort and another to balance the LE GnRH-ant and GnRH-a groups to form the PSM 2 cohort.

To create comparable groups, the variables and coefficients matched by the two queues were slightly different. Variables in the PSM 1 included age, AMH, BMI, factors of infertility, duration of infertility, total gonadotropins, and total days of GnRH-ant. The matching ratio was 1:1, and the matching range of the score was 0.005. The variables in PSM 2 included age, AMH, BMI, factors of infertility, and duration of infertility. The matching ratio was 1:1, and the matching range of the score was 0.01.

Following PSM to create characteristically similar groups, an interaction analysis was performed on progesterone levels on trigger day change, with the total number of retrieved oocytes increasing in PSM 1 and 2 cohorts.

Premature LH surge may lead to an increase in progesterone and also result in early ovulation. Therefore, we divided LH levels on trigger day into three equal groups (tertile) and compared progesterone levels in each tertile.

Besides progesterone levels on trigger day, four other variables were added to describe the changes in progesterone levels: 1) P1.5, i.e., the proportion of women with a progesterone level of >1.5 ng/mL. Progesterone levels on the trigger day were converted to a binary variable with 1.5 ng/mL as the boundary. Progesterone levels of > 1.5 ng/mL on trigger day can affect the results of embryo transfer, and it is recommended to freeze all embryos before transferring (21). 2) The progesterone to oocyte index (POI), i.e., the relative value of the ratio of progesterone to aspirated oocytes. A high POI predicts poor clinical pregnancy and live birth rates in fresh IVF/ICSI cycles (22). Extreme situations, such as early ovulation, due to which a very few oocytes are obtained on the day of egg retrieval, might have affected the results. Therefore, data on extreme cases (upper and lower 1% of the data distribution) were removed and the remaining data were recorded as POI. 3) The P/E2 ratio, calculated as P (pg/mL)/E2 (pg/mL). 4) P/E2 0.55, i.e., the proportion of women with a P/E2 ratio of > 0.55. Progesterone levels on trigger day were converted into a binary variable, with 0.55 as the boundary. A regression analysis was used to explore the relationship between these four variables and medication regimens.

A student’s t-test was used for normal distribution data, and a Kruskal–Wallis test was used for non-normal distribution data. A chi-square test was used for counting data. If the theoretical number of counting variables was less than 10, a Fisher’s exact test was used. All analyses were performed using Empower (R) (X&Y Solutions, Inc, Boston, MA, USA) and R software (version 3.3.3, The R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was established at P < 0.05.

**RESULTS**

Before PSM, patients in the LE GnRH-ant group were older (P < 0.001) and had a higher BMI (P = 0.008) and a frequency of ovulation disorder and male factor (P < 0.001) than those in the other two groups (Supplemental Table 1). **Supplemental Table 2** presents the results of ovulation induction before PSM.

After PSM, 266 patients in the GnRH-ant group were successfully matched to 266 patients in the LE GnRH-ant group (PSM 1 cohort, **Table 1**). There was no statistically significant difference in patient characteristics between the two groups; however, there were significant differences in treatment results between the two groups (PSM 1 cohort, **Table 2**). Patients in the LE GnRH-a group presented higher progesterone levels (1.22 ± 0.95 ng/mL vs 0.86 ± 0.60 ng/mL, P < 0.001), with higher proportion of patients with a progesterone level > 1.5 ng/mL (24.81% vs 7.52%, P < 0.001); higher P/E2 ratio (0.75 ± 0.58 vs 0.43 ± 0.60, P < 0.001), with higher proportion of patients with a P/E2 ratio >0.55 (52.63% vs 17.67%, P < 0.001); higher POI (132.47 ± 112.07 pg/mL vs 100.84 ± 93.87 pg/mL, P < 0.001), and lower oestradiol levels on trigger day (2,259.90 ± 1,779.14 pg/mL vs 2,773.54 ± 1,830.26 pg/mL, P < 0.001) than those in the GnRH-ant group.
In the PSM 2 cohort, 283 patients in the GnRH-a group were successfully matched to 283 patients in the LE GnRH-ant group (PSM 2 cohort, Table 1). There was no statistically significant difference in patient characteristics between the two groups. In the LE GnRH-ant group, the total Gn used was less than that of the GnRH-a group (1988.19 ± 755.86 IU vs 2,664.80 ± 910.41 IU, *P* < 0.001), and the total stimulation days were also relatively less than those in the GnRH-a group (9.72 ± 2.05 days vs 12.51 ± 2.18 days, *P* < 0.001). However, there were significant differences in treatment results between the two groups (PSM 2 cohort, Table 2). Patients in the LE GnRH-a group presented higher progesterone levels on trigger day (1.23 ± 0.91 ng/mL vs 0.98 ± 0.61 ng/mL, *P* < 0.001), with higher proportion of patients with a progesterone level > 1.5 ng/mL (25.45% vs 12.70%, *P* < 0.001); higher P/E2 ratio (0.72 ± 0.53 vs 0.32 ± 0.21, *P* < 0.001), with higher proportion of patients with a P/E2 ratio > 0.55 (51.94% vs 11.31%, *P* < 0.001); higher POI (131.23 ± 109.62 pg/mL vs 97.28 ± 89.77 pg/mL, *P* < 0.001), lower oestradiol levels on trigger day (2,347.71 ± 1,781.67 pg/mL vs 3,658.56 ± 1972.96 pg/mL, *P* < 0.001), and less retrieved oocytes (13.30 ± 8.56 vs 16.78 ± 8.47, *P* < 0.001) than those in the GnRH-a group.

In the PSM 1 cohort, to determine whether high level of LH in the LE GnRH-ant protocol is caused due to high progesterone levels, LH was divided into three groups (tertiles). The progesterone level, proportion of patients with a progesterone level > 1.5 ng/mL, P/E2 ratio, and proportion of patients with a P/E2 ratio > 0.55 in the LE

### TABLE 1 | Baseline characteristics of patients and the features of ovulation induction after propensity score matching.

| Variables                      | GnRH-a LE (n = 283) | LE PSM 2 (n = 283) | *P* value |
|--------------------------------|---------------------|--------------------|-----------|
| Duration of infertility (years) | 3.86 ± 3.06         | 4.08 ± 3.23        | 0.401     |
| Age (years)                    | 32.00 ± 4.69        | 32.18 ± 5.05       | 0.648     |
| BMI (kg/m²)                    | 21.86 ± 3.08        | 22.06 ± 3.01       | 0.448     |
| AMH (ng/mL)                    | 3.72 ± 2.73         | 3.79 ± 2.93        | 0.802     |
| Basic FSH (mIU/mL)             | 7.99 ± 3.92         | 7.65 ± 3.51        | 0.301     |
| Basic LH (mIU/mL)              | 45.31 ± 35.35       | 49.15 ± 54.49      | 0.336     |
| Basic P (ng/mL)                | 0.40 ± 0.94         | 0.49 ± 1.31        | 0.322     |
| Total number of retrieved oocytes | 12.16 ± 7.99       | 12.26 ± 8.39       | 0.889     |
| Total GnRH-ants (mg)           | 0.27 ± 0.18         | 0.45 ± 2.87        | 0.332     |
| Factors of infertility         | 0.190               |                    |           |
| Ovulation disorder             | 32 (12)             | 44 (16.5)          |           |
| Tubal factors                  | 164 (61.7)          | 142 (53.4)         |           |
| Endometriosis                  | 6 (2.3)             | 19 (4.9)           |           |
| Male factors                   | 27 (10.2)           | 28 (10.5)          |           |
| Other                          | 37 (13.9)           | 39 (14.7)          |           |
| Total gonadotropins (IU)       | 1,951.64 ± 714.07   | 1,945.63 ± 675.96  | 0.921     |
| Days of stimulation            | 9.49 ± 1.94         | 9.65 ± 2.05        | 0.374     |
| Total GnRH-ants (mg)           | 1.35 ± 0.47         | 1.37 ± 0.49        | 0.726     |

GnRH-a, gonadotropin-releasing hormone-agonist; GnRH-ant, gonadotropin-releasing hormone-antagonist; LE GnRH-ant, GnRH-ant + letrozole; BMI, body mass index; AMH, anti-Mullerian hormone; LH, Luteinizing hormone; FSH, follicle-stimulating hormone; P, progesterone; E2, oestradiol.

### TABLE 2 | Results of ovulation induction after propensity score matching.

| Variables                      | GnRH-a LE (n = 283) | LE PSM 2 (n = 283) | *P* value |
|--------------------------------|---------------------|--------------------|-----------|
| Estradiol levels on trigger day (pg/mL) | 12.26 ± 3.39       | 12.26 ± 3.89       | 0.889     |
| LH levels on trigger day (mIU/mL)     | 2,259.90 ± 1,779.14| 2,259.90 ± 1,779.14| 0.901     |
| P levels on trigger day (ng/mL)       | 0.76 ± 0.58         | 0.72 ± 0.58        | <0.001    |
| POI (pg/mL)                         | 123.47 ± 112.07     | 123.47 ± 112.07    | <0.001    |
| P1.5                               |                     |                    |           |
| ≤1.5 (ng/mL)                       | 246 (92.48%)        | 200 (75.19%)       | 0.001     |
| >1.5 (ng/mL)                       | 247 (87.30%)        | 247 (87.30%)       | 0.001     |
| PE2 0.55                           | 36 (12.70%)         | 36 (12.70%)        | 0.001     |
| ≤0.55                              | 219 (82.33%)        | 219 (82.33%)       | <0.001    |
| >0.55                              | 251 (88.69%)        | 251 (88.69%)       | <0.001    |

GnRH-a, gonadotropin-releasing hormone-agonist; GnRH-ant, gonadotropin-releasing hormone-antagonist; LE GnRH-ant, GnRH-ant + letrozole; LH, Luteinizing hormone; P, progesterone; E2, oestradiol; P1.5, the proportion of women with a progesterone level > 1.5 ng/mL; POI, relative value of progesterone to an aspirated oocytes ratio; PE2 0.55, the proportion of women with a PE2 ratio > 0.55.
GnRH-ant group were significantly higher than those in the GnRH-ant group in each subgroup analysis (Supplemental Table 3).

In the PSM 1 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL with an increase in all retrieved oocyte in the LE GnRH-ant group (β 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-ant group (β 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001) (**Figure 2**), with P for interaction being 0.0018, which suggest, with increased retrieved oocytes, women in the LE GnRH-ant group had a greater increase in progesterone levels than women in the GnRH-ant group. In the PSM 2 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL with an increase in every retrieved oocyte in the LE GnRH-ant group (β 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-ant group (β 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001) (**Figure 3**), with P for interaction was 0.0002, which suggest, with increased retrieved oocytes, women in the LE GnRH-ant group had a greater increase in progesterone levels than women in the GnRH-a group.

**DISCUSSION**

This retrospective matched cohort study explored the influence of adopting antagonist protocols that introduced LE during ovulation stimulation on trigger day on the hormone levels in infertile females undergoing IVF/ICSI. The results indicated that the antagonist protocols that introduced LE increased the risk of high progesterone levels on trigger day.

Many studies have shown that progesterone produced in IVF/ICSI is related to the number of follicles (23, 24). In this study, we hypothesised that late elevations in follicular blood progesterone might be owing to the following reasons: 1) An increase in progesterone secretion from the recruited follicles; the greater the number of follicles, the higher the progesterone level, which could be induced by any protocol; 2) pathological progesterogen, which is related to the premature luteinisation of follicles and decreased follicle quality. This increase is always accompanied with LH surge; and 3) use of LE.

In the PSM 1 cohort, increased progesterone levels strongly point to LE use. First, progesterone levels are much higher in the LE GnRH-ant group under the conditions where the number of eggs was similar (**Table 2**). Second, **Figure 2** provides evidence that with increased eggs, women in the LE GnRH-ant group had a greater increase in progesterone levels than women in the GnRH-ant group. These evidences eliminate the possibility that the increased progesterone levels in the LE GnRH-ant group are attributed to the increase in the number of eggs. Third, there is no association between the increase in LH and progesterone levels according to the tertiles stratified analysis. Progesterone in the LE GnRH-ant group increased by 0.40 ng/mL even if LH levels were comparatively lower (<2.39 mIU/mL) than those in the GnRH-ant group. These evidences eliminate the possibility that the protocol is an effect modifier that affects progesterone levels and the number of eggs in the PSM 2 cohort. Progesterone levels are relatively easier to increase with the increase in the number of eggs in the LE GnRH-ant group.

Similarly, the progesterone levels of the late follicles were also higher in the LE GnRH-ant group than in the GnRH-a group in the PSM 2 cohort. **Figure 3** provides evidence that the protocol is an effect modifier that affects progesterone levels and the number of eggs in the PSM 2 cohort. Progesterone levels are relatively easier to increase with the increase in the number of eggs in the LE GnRH-ant group.

Our research indicates that LE poses a strong risk of increasing progesterone levels. Regarding the mechanism through which LE elevates progesterone, we hypothesised LE inhibited the production of oestrogen (mainly oestradiol), resulting in the accumulation of oestrogen synthesis precursors and androgens (e.g., testosterone and androstenedione) (14). Once the accumulation of androgens reaches a certain threshold, progesterone accumulates, increasing its levels in the blood, which has also been proven in previous studies (14, 19).

High progesterone levels have a negative impact on the pregnancy rate on the trigger day of the fresh cycle. Studies have demonstrated that an increase in progesterone during the late follicular phase is associated with decreased pregnancy potential (25). A cut-off level of 1.5 ng/mL appeared to discriminate between those with and without negative pregnancy outcomes (18, 19). The decreased endometrial receptivity owing to an early increase in progesterone levels may explain the decrease in pregnancy rates (26).

Other studies have shown that progesterone level has a marked negative effect in the group where < 5 oocytes are retrieved; however, this is not observed among high responders (27). Some researchers believe that the number of mature follicles is very important in the evaluation of progesterone, so POI and P/E2 ratio were offered to assess the effects of progesterone. The POI values greater than 0.36 ng/mL/oocyte result in a low clinical pregnancy rate and a live birth rate of 8.0% and 5.9%, respectively (28). Shufaro et al. reported that the POI is inversely related to pregnancy rate and concluded that the POI is better correlated with IVF outcomes than blood progesterone levels (29). Besides POI, the P/E2 ratio was proposed as...
important when considering the number of developing follicles in COS cycles. A P/E2 ratio > 0.55 affects the clinical pregnancy rate, and the P/E2 ratio is the only independent prognostic factor for cycle outcomes in females undergoing cleavage-stage embryo transfer (30). These findings emphasise the complexity of analysing data on end-COS progesterone. In this study, these indicators were considered to evaluate the potential effects of LE. The indicators were upregulated in the LE GnRH-ant group. However, in this study, we can only prove the elevated progesterone associated with LE, the effects of LE on pregnancy rate and live birth rate need to be further analysed.

In contrast to previous studies (17–20), this study included a large sample size with high, normal, and low response groups, resulting in different eggs obtained after appropriate stimulation. Figure 2 and Figure 3 show that with increased eggs, women in the LE GnRH-ant group had a greater increase in progesterone levels than women in the GnRH-ant group or the GnRH-a group. Consequently, fewer retrieved oocytes result in a slight increase in progesterone levels, and therefore a slight difference is observed between the groups. We speculated that when there are fewer eggs, the precursor of oestrogen synthesis and androgen accumulation caused by LE is less, and progesterone accumulation is even lower, which makes it difficult to find a significant difference in LE arms. This may explain the cause of rising testosterone levels in parts of the follicular fluid, without detecting the increase in progesterone, in LE-related studies, with poor responders (31). Meanwhile, an increase in the number of follicles means an increase in the accumulation of precursors in the presence of LE. A study has reported that in patients with high responses (the average number of retrieved oocytes is 12–13), the progesterone levels significantly increase and the proportion of patients with a progesterone level >1.5 ng/mL also increases significantly (19). In patients with normal responses (the average number of retrieved oocytes is 7.7–8.0), researchers reported that progesterone levels show a significant increase; however, no increase in the proportion of women with a progesterone level >1.5 ng/mL is observed (14). A small sample size may also be responsible for no difference in the proportion of patients with a progesterone level >1.5 ng/mL in some studies.

This study is a retrospective observational study, with an inherent challenge of bias and/or confounders. PSM was efficient in minimising bias due to confounding. PSM matched two groups of study participants with similar or identical propensity scores, to create samples approximate to a randomised trial by directly comparing outcomes between individuals. PSM can improve estimation of the causal treatment effect in an observational study by mimicking some of the statistical properties of a randomised controlled trial (32). Therefore, we chose PSM instead of regression analyses for the confounders in this study.

The current study had limitations. First, the detection of serum progesterone levels was based on results obtained by chemiluminescence, but not mass spectrometry, which may have affected their accuracy. Second, there were some unmeasurable confounders in this single-centre retrospective PSM cohort study, and this limitation can be overcome by RCT studies with sufficient power of test. Third, changes in serum progesterone-androgen-oestrogen metabolism were not detected to confirm the source of the rising progesterone. These issues should be addressed in future research.

In conclusion, the GnRH-ant protocols that utilise LE increase the risk of higher progesterone levels, P/E2 ratio, POI, the proportion of females with a P/E2 ratio >0.55, as well as a higher proportion of those with a progesterone level >1.5 ng/mL on trigger day. These results suggest LE should be handled with caution during ovarian stimulation for IVF/ICSI and that a greater focus should be on high serum progesterone levels. However, these results still need to be further confirmed by a well-designed RCT study with sufficient power of test.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT

The study protocol was approved by the Institutional Ethics Committee of Dongguan Songshan Lake (SSL) Central Hospital (202005010). The requirement for informed consent was waived because of the retrospective nature of the study.

AUTHOR CONTRIBUTIONS

RL: Conceptualisation, methodology, formal analysis, writing—original draft preparation, writing—reviewing and editing, project administration, funding acquisition. L.Z.: Investigation, data curation, writing—reviewing and editing. XC: Resources, investigation. All authors have read and contributed to the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Yang AM, Cui N, Sun YF, Hao GM. Letrozole for Female Infertility. Front Endocrinol (2021) 12:676133. doi: 10.3389/fendo.2021.676133
2. Pritts EA. Letrozole for Ovulation Induction and Controlled Ovarian Hyperstimulation. Curr Opin Obstet Gynecol (2010) 22:289–94. doi: 10.1097/GCO.0b013e32833beebf
3. Bonardi B, Massarotti C, Bruzzone M, Goldrat O, Mangili G, Anserini P, et al. Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-Administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Front Oncol (2020) 10:574669. doi: 10.3389/fonc.2020.574669
4. Pundir J, Achilli C, Bhide P, Sabatini L, Legro RS, Rombauts L, et al. Risk of Foetal Harm With Letrozole Use in Fertility Treatment: A Systematic Review and Meta-Analysis. Hum Reprod Update (2021) 27:474–85. doi: 10.1093/humupd/dmaa055
5. Zhang J, Wei M, Bian X, Wu L, Zhang S, Mao X, et al. Letrozole-Induced Frozen Embryo Transfer Cycles are Associated With a Lower Risk of Hypertensive Disorders of Pregnancy Among Women With Polycystic Ovary Syndrome. Am J Obstet Gynecol (2021) 225(1):59.e1–9. doi: 10.1016/j.ajog.2021.01.024
6. Zhang J, Liu H, Wang Y, Mao X, Chen Q, Fan Y, et al. Letrozole Use During Frozen Embryo Transfer Cycles in Women With Polycystic Ovary Syndrome. Fertil Steril (2019) 112(2):371–7. doi: 10.1016/j.fertnstert.2019.04.014
7. Li D, Khor S, Huang J, Chen Q, Lyu Q, Cai R, et al. Frozen Embryo Transfer in Mildly Stimulated Cycle With Letrozole Compared to Natural Cycle in Ovulatory Women: A Large Retrospective Study. Front Endocrinol (Lausanne) (2021) .12:677689. doi: 10.3389/fendo.2021.677689
8. Zhang W, Liu Z, Zhang J, Ren B, Liu M, Li J, et al. Comparison of Perinatal Outcomes of Letrozole-Induced Ovulation and Hormone Replacement Therapy Protocols in Patients With Abnormal Ovulation Undergoing Frozen-Thawed Embryo Transfer: A Propensity Score Matching Analysis. Front Endocrinol (Lausanne) (2022) 13:837731. doi: 10.3389/fendo.2022.837731
9. Tatsuni T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito H. Pregnancy and Neonatal Outcomes Following Letrozole Use in Frozen–Thawed Single Embryo Transfer Cycles. Hum Reprod (2017) 32:1244–8. doi: 10.1093/humrep/dex066
10. Zhang J, Li Z, Sun L, Guan Y, Du M. Comparison of Pregnancy and Neonatal Outcomes of Single Frozen Blastocyst Transfer Between Letrozole-Induction and HRT Cycles in Patients With Abnormal Ovulation. Front Endocrinol (2021) 12:664072. doi: 10.3389/fendo.2021.664072
11. Mai Q, Hu X, Yang G, Luo Y, Huang K, Yuan Y, et al. Effect of Letrozole on Moderate and Severe Early-Onset Ovarian Hyperstimulation Syndrome in High-Risk Women: A Prospective Randomized Trial. Am J Obstet Gynecol (2017) 216:42.e1–42.e10. doi: 10.1016/j.ajog.2016.08.018
12. Rose BI, Brown SE. A Review of the Physiology Behind Letrozole Applications in Infertility: Are Current Protocols Optimal? J Assist Reprod Genet (2020) 37:2093–104. doi: 10.1007/s10815-020-01892-6
13. Bechtjejew TN, Nadai MN, Nasiri CO, Martins WP. Clomiphene Citrate and Letrozole to Reduce Follicle-Stimulating Hormone Consumption During Ovarian Stimulation: Systematic Review and Meta-Analysis. Ultrasound Obstet Gynecol (2017) 50:315–23. doi: 10.1002/uog.17442
14. Bülow NS, Skouby SO, Warzecha AK, Udenaard H, Andersen CY, Holt MD, et al. Impact of Letrozole Co-Treatment During Ovarian Stimulation With Gonadotrophins for IVF: A Multicentre, Randomized, Double-Blinded Placebo-Controlled Trial. Hum Reprod (2022) 37:309–21. doi: 10.1093/humrep/deab249
15. Alivii C, Marci R, Vallone R, Conforti A, Di Bella F, Strina E, et al. High Progesterone Levels During the Luteal Phase Related to the Use of an Aromatase Inhibitor in Breast Cancer Patients. Eur Rev Med Pharmacol Sci (2017) 13:3134–8.
16. Goldrat O, Geryv C, Englert Y, Delbaere A, Demeestere I. Progesterone Levels in Letrozole Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. Hum Reprod (2015) 9:2184–9. doi: 10.1093/humrep/dev155
17. Mukherjee S, Sharma S, Chakravarty BN. Letrozole in a Low-Cost In Vitro Fertilization Protocol in Intracytoplasmic Sperm Injection Cycles for Male Factor Infertility: A Randomized Controlled Trial. J Hum Reprod Sci (2012) 5:170–4. doi: 10.4103/0974-1209.101014
18. Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsbøll S, Andersen AN. Short-Term Androgen Priming by Use of Aromatase Inhibitor and hCG Before Controlled Ovarian Stimulation for IVF. A randomized Controlled trial. Hum Reprod (2008) 23:1820–9. doi: 10.1093/humrep/den131
19. Yang X, Lin G, Lu G, Gong F. Letrozole Supplementation During Controlled Ovarian Stimulation in Expected High Responders: A Pilot Randomized Controlled Study. Reprod Biol Endocrinol (2019) 17:43. doi: 10.1186/s12958-019-0483-x
20. Mehdinejadiani S, Amidi F, Mehdi zadeh M, Barati M, Pazhoohani A, Alyasian A, et al. Effects of Letrozole and Clomiphene Citrate on West Signaling Pathway in Endometrium of Polycystic Ovarian Syndrome and Healthy Women. Biol Reprod (2019) 100:641–8. doi: 10.1095/biomej.117.0187
21. Venetis CA, Kolibianakis EM, Bosdou JK, Lainas GT, Sfontouris IA, Tarlatzis BC, et al. Basal Serum Progesterone and History of Elevated Progesterone on the Day of hCG Administration are Significant Predictors of Late Follicular Progesterone Elevation in GnRH Inhibitor IVF Cycles. Hum Reprod (2016) 31:1859–65. doi: 10.1093/humrep/dev141

FUNDING

This research was funded by the talent introduction program initiated by Dongguan SSL Central Hospital (#YJ-20190001), and the key project of social science and technology development of Dongguan City in 2019 (201950715024177).

ACKNOWLEDGMENTS

We thank Professor Liu Fenghua from the Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangdong Province, People’s Republic of China for her assistance in analysing the results.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.904089/full#supplementary-material
22. Merviel P, Bouée S, Jacamon AS, Chabaud JJ, Le Martelot MT, Roche S, et al. Progesterone Levels on the Human Chorionic Gonadotropin Trigger Day Affect the Pregnancy Rates for Embryos Transferred at Different Stages of Development in Both General and Selected IVF/ICSI Populations. *BMC Pregnancy Childbirth* (2021) 21:363. doi: 10.1186/s12884-021-03832-3

23. Mahran A, Khairy M, Elkhateeb R, Hegazy AR, Abdelmeged A, Batíha GE, et al. The Value of Serum Progesterone Level on Day of Human Chorionic Gonadotrophin Administration/Metaphase II Oocyte Ratio in Predicting IVF/ICSI Outcome in Patients With Normal Ovarian Reserve. *J Ovarian Res* (2021) 14:52. doi: 10.1186/s13048-021-00800-5

24. Kasum M, Simunić V, Vrčić H, Stanić P, Orešković S, Beketić-Oresković L. Follicular Progesterone Elevations With Ovulation Induction for IVF. *Gynecol Endocrinol* (2014) 30:537–41. doi: 10.3109/09513590.2014.916263

25. Venetis CA, Kolibianakis EM, Bosdou JK, Lainas GT, Sfontouris IA, Tarlatzis BC, et al. Estimating the Net Effect of Progesterone Elevation on the Day of hCG on Live Birth Rates After IVF: A Cohort Analysis of 3296 IVF Cycles. *Hum Reprod* (2015) 30:684–91. doi: 10.1093/humrep/deu362

26. Lawrenz B, Labarta E, Fatemi H, Bosch E. Premature Progesterone Elevation: Targets and Rescue Strategies. *Fertil Steril* (2018) 109:577–82. doi: 10.1016/j.fertnstert.2018.02.128

27. Griesinger G, Mannaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone Elevation Does Not Compromise Pregnancy Rates in High Responders: A Pooled Analysis of In Vitro Fertilization Patients Treated With Recombinant Follicle-Stimulating Hormone/Gonadotropin-Releasing Hormone Antagonist in Six Trials. *Fertil Steril* (2013) 100:1622–8.e1. doi: 10.1016/j.fertnstert.2013.08.045

28. Grin L, Mizrachi Y, Cohen O, Lazer T, Liberty G, Meltzer S, et al. Does Progesterone to Oocyte Index Have a Predictive Value for IVF Outcome? A Retrospective Cohort and Review of the Literature. *Gynecol Endocrinol* (2018) 34:638–43. doi: 10.1080/09513590.2018.1431772

29. Shufaro Y, Sapir O, Oron G, Ben Haroush A, Garor R, Pinkas H, et al. Progesterone-To-Follicle Index is Better Correlated With In Vitro Fertilization Cycle Outcome Than Blood Progesterone Level. *Fertil Steril* (2015) 103:669–74.e3. doi: 10.1016/j.fertnstert.2014.11.026

30. Elgindy EA. Progesterone Level and Progesterone/Estradiol Ratio on the Day of hCG Administration: Detrimental Cutoff Levels and New Treatment Strategy. *Fertil Steril* (2011) 95:1639–44. doi: 10.1016/j.fertnstert.2010.12.065

31. Lee VC, Chan CC, Ng EH, Yeung WS, Ho PC. Sequential Use of Letrozole and Gonadotrophin in Women With Poor Ovarian Reserve: A Randomized Controlled Trial. *Reprod BioMed Online* (2011) 23:380–8. doi: 10.1016/j.rbmo.2011.05.012

32. Haukoos JS, Lewis RJ. The Propensity Score. *JAMA* (2015) 314(15):1637–8. doi: 10.1001/jama.2015.13480

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Zhou, Chen, He and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.